Gazya for lupus in Brazil starts with a regulator, not a payment decision. On 13 October 2026 Anvisa approved a new use for Gazya (obinutuzumab). Anvisa is Brazil's health regulator. Obinutuzumab is a monoclonal antibody. A monoclonal antibody is a lab-made protein aimed at one target on a cell. Systemic lupus erythematosus, SLE, is an autoimmune disease. The immune system attacks the patient's own tissues.
Anvisa says the medicine can be used in adults with active, moderate to severe SLE who have autoantibodies and are already on standard treatment. An autoantibody is an antibody directed at the body's own tissues. Anvisa approval is not a decision that the public system, the SUS, will pay. The SUS is Brazil's public health system. A private health plan is a separate route.
What Anvisa approved
Anvisa's announcement describes the new indication in those words. The decision was published in the Diário Oficial da União as Resolução 3.970/2026. The Diário Oficial is Brazil's official gazette.
Anvisa describes this as a new use of a medicine already on the market. Roche says the medicine is approved in 100 countries for various types of blood cancer, and for adults with lupus nephritis in the United States and the European Union. Lupus nephritis is kidney disease caused by lupus. Those Roche sentences are not the Brazilian SLE indication, and they are not a count of patients in Brazil.
Anvisa describes obinutuzumab as a humanised type II anti-CD20 monoclonal antibody. CD20 is a protein on B cells. B cells are immune cells. Anvisa says the medicine causes a large and long-lasting depletion of B cells, and that those cells play a central role in SLE.
Anvisa frames the approval around patients whose disease stays active despite existing conventional and biological therapies. It describes repeated flares or continuous corticosteroid use, and the long-term side effects of steroids. Anvisa lists three benefits: lower disease activity, fewer flares, and a sustained reduction in corticosteroid exposure. Those are the regulator's words about the indication. They are not a Brazilian headcount and they are not a SUS budget line.
The trial
Anvisa's announcement does not name the trial. Roche's public data come from ALLEGORY. ALLEGORY is a phase III, randomised, double-blind, placebo-controlled study in adults with SLE on standard therapy. The New England Journal of Medicine published the results online on 6 March 2026. The print version followed on 16 July 2026.
The figures in this section are trial results. They are not a count of patients in Brazil. They are not SUS funding.
Roche says 76.7% of patients on obinutuzumab plus standard therapy reached the primary endpoint, a response on the SLE Responder Index 4 at week 52. Roche says 53.5% did so on placebo plus standard therapy. The adjusted difference was 23.1%, with p<0.001. The NEJM abstract says 303 patients were randomised, 151 to obinutuzumab and 152 to placebo. It says patients with proliferative or membranous lupus nephritis were not included.
Roche and the NEJM abstract also report secondary results.
- Steroid reduction: 80.0% of obinutuzumab patients reduced their glucocorticoid dose to 7.5 mg per day or less, sustained from week 40 to week 52, against 54.1% on placebo.
- Flares: time to first flare on the BILAG index improved, with a hazard ratio of 0.58. A hazard ratio compares the rate of an event. It is not a patient count.
- Remission: 33.8% against 13.8%.
- BICLA response at week 52: 62.0% against 40.1%.
Roche says safety was consistent with the known profile, with no new safety signals. None of these percentages is a count of people with SLE in Brazil, or a sum the SUS will spend.
The NEJM author and collaborator list includes Brazilian institutions. They include the Bahiana School of Medicine and Public Health and the Federal University of Bahia in Salvador, and Centro Mineiro de Pesquisa in Juiz de Fora. The paper lists centres. It does not, in the sources used here, give a Brazilian patient count.
In the NEJM paper, doses in the trial were given on day 1 and at weeks 2, 24 and 26. That is the trial schedule. The Anvisa note used here does not set a Brazilian dose calendar, and it does not say the SUS will fund those infusions.
Roche said in April 2026 that the FDA had accepted its US application for SLE and expected a decision by December 2026. Roche said ALLEGORY data had also been filed with the European Medicines Agency. Those sentences are about other regulators. They are not a Brazilian payment decision. If a foreign health-technology body has not assessed this use, one private-plan route in Brazil that depends on such a body is not yet open. That is a reading of the statute below. It is not a prediction of the SUS budget.
Public system
Anvisa approval is not a public-system payment decision. In the SUS, adding a medicine or changing a clinical protocol is the job of the Ministry of Health. The ministry is advised by CONITEC, the Comissão Nacional de Incorporação de Tecnologias no SUS, under Lei 12.401/2011.
The law says CONITEC's report must consider the scientific evidence accepted by the registration authority, and a comparative economic evaluation against technologies already in the SUS. The process includes a public consultation. It includes a public hearing before the decision when the issue justifies one.
The same law bars the SUS from paying for a medicine, or a use, that Anvisa has not authorised. A registered indication is the entry ticket for a public route. It is not the payment decision.
Lei 12.401/2011 sets the incorporation process at no more than 180 days from the request, extendable by 90 calendar days. Decreto 7.646/2011 then gives the ministry's technical areas a maximum of 180 days after a positive decision is published to make the technology available. The clock starts when a request is filed. These sources do not say a request has been filed, and they do not say the SUS will fund Gazya.
For how CONITEC assessments are structured, see the guide to CONITEC technology assessment in Brazil.
Private plans
Private health plans follow the coverage list of the ANS, the Agência Nacional de Saúde Suplementar. The list is called the rol. Under Lei 14.307/2022, an update to the rol must be completed within 180 days of the request, extendable by 90 calendar days.
Lei 14.454/2022 added a further rule. When a doctor prescribes a treatment that is not on the rol, the plan must authorise coverage if there is proof of efficacy based on scientific evidence and a treatment plan, or if CONITEC has recommended it, or if at least one internationally renowned health-technology body has recommended it, provided that body also approved it for its own population.
That last condition depends on a foreign assessment existing. These sources do not say a Brazilian plan has authorised Gazya, and they do not say the SUS has.
Accounts
National rules set the frame. Use of the medicine, if a payer agrees, happens in named services.
Obinutuzumab is given as an infusion. A service needs a place to infuse it, staff to monitor the patient, and a way to obtain the product. For SLE, that is often a rheumatology service in a hospital or a specialised infusion centre. The trial schedule above is the NEJM schedule. The Anvisa note used here does not set that schedule.
Questions a team can ask, without turning the trial into a national count:
- Which rheumatology centres see adults with active, moderate to severe SLE on standard treatment?
- Do those centres infuse biologics, or do they refer?
- Who signs off on adding a biologic to the centre's list?
- What share of that centre's patients use a private plan, and which plan? A centre's mix is not a national SUS figure.
Many people with complex SLE are followed in university hospitals and state reference centres in the SUS. Until a ministry decision, those accounts work inside the current protocol. Rheumatologists there may train others and join a public consultation. That role is not a funding decision.
In the private system, the hospital, the rheumatologist and the health plan each have a part. Plan rules differ. Mapping which plans cover patients at priority accounts is a first research step. It is not evidence that coverage has been granted.
Prescribers
Rheumatologists choose patients inside whatever access exists. A survey can ask who they see as a candidate, where they would place an anti-CD20 option next to current therapies, how much weight they give to lowering steroids, what they expect from a plan or a hospital committee, and whether patients can travel for infusions. Split public and private practice. Survey answers are not a public-system budget.
The ALLEGORY steroid and flare results are global trial results. A Brazilian payer may ask what flares and steroid use cost in Brazilian practice. That question is a reason to collect local data. The trial percentages are not that local cost, and they are not a funding line.
CONITEC's process includes public consultation. Physician and patient evidence can be prepared for that stage if a request is filed. These sources do not say a request has been filed.
Access to rheumatologists, infusion centres and private plans differs by region. A sample limited to the largest cities misses other regions. It also does not become a national patient count.
Messages
Anvisa's own wording points to a large and long-lasting depletion of B cells, and to three benefits: disease activity, flares and corticosteroid exposure. Medical education can explain those words. It should not go past the label and the published trial.
A rheumatologist, a hospital pharmacist and a health-plan medical director do not ask the same question. Test messages with each group. A message test is not a claim that the SUS will pay.
Price rules
Medicine prices in Brazil are regulated by CMED, the Câmara de Regulação do Mercado de Medicamentos, created by Lei 10.742/2003. The law requires companies to follow its rules when setting and adjusting prices. For an existing product with a new indication, the sources used here do not state a new list price. Ask each buyer how it actually pays: a public hospital, a private hospital, or a health plan. A payment route is not proof that the route is open for this indication.
Ninety days
- Days 1 to 30: list rheumatology accounts, infusion capacity and the main payer at each account. Ask a short set of rheumatologists how they sequence treatment today.
- Days 31 to 60: interview hospital pharmacy and committee members, and medical directors at major plans, on the evidence they ask for. Record what they ask. Do not record it as a SUS decision.
- Days 61 to 90: collect local evidence on flares and steroid use. Set a baseline of prescribing intent. Keep the ALLEGORY percentages labelled as trial results.
Frequently asked questions
What did Anvisa approve for Gazya?
On 13 October 2026, Anvisa approved a new indication for Gazya (obinutuzumab) in adults with active, moderate to severe, autoantibody-positive systemic lupus erythematosus on standard treatment, under Resolução 3.970/2026. Anvisa is Brazil's health regulator. This approval is not a decision that the public system will pay.
What benefits did Anvisa highlight?
Anvisa lists lower disease activity, fewer flares and a sustained reduction in corticosteroid exposure. Those words describe the indication. They are not a count of patients in Brazil and they are not a SUS budget.
Does Anvisa approval mean SUS patients can get it?
No. Anvisa approval is not a public-system payment decision. SUS incorporation needs a Ministry of Health decision advised by CONITEC. After a positive decision is published, Decreto 7.646/2011 gives technical areas up to 180 days to make the technology available.
How long does a CONITEC decision take?
Lei 12.401/2011 sets a maximum of 180 days from the request, extendable by 90 days. The clock starts when a request is filed, not when Anvisa approves the indication.
How do private health plans cover medicines not on the ANS rol?
Under Lei 14.454/2022, a plan must cover a prescribed treatment outside the rol when there is scientific evidence of efficacy and a treatment plan, or a CONITEC recommendation, or a recommendation from an internationally renowned health-technology body that also approved it for its own population.
What should brand teams research first?
Which rheumatology accounts see active lupus, whether they can infuse a medicine, and which payer each account uses. The ALLEGORY trial percentages are not a Brazilian patient count or a SUS funding figure.
Plan your Brazil access research with BioNixus
BioNixus has run primary market research since 2012, with physician, payer and account fieldwork across 48 countries. We are field office for LATAM, as part of our Latin America expansion. See pharmaceutical market research in Brazil.
If you are preparing an immunology launch in Brazil, contact our team.
This article summarises public regulatory information. It is not medical or legal advice, and it does not promote any medicine. Anvisa approval is not a SUS payment decision.
Sources
All accessed 17 October 2026.
- Anvisa, "Anvisa aprova novo medicamento para lúpus eritematoso sistêmico", 13 October 2026: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-novo-medicamento-para-lupus-eritematoso-sistemico
- Roche media release, ALLEGORY data published in NEJM, 6 March 2026: https://www.roche.com/media/releases/med-cor-2026-03-06
- Roche media release, FDA accepts application for SLE, 21 April 2026: https://www.roche.com/media/releases/med-cor-2026-04-21
- Furie RA et al., "Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus", N Engl J Med 2026;395(3):243-254, doi 10.1056/NEJMoa2516150 (abstract via PubMed PMID 41789864): https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 and https://pubmed.ncbi.nlm.nih.gov/41789864/
- Lei 10.742/2003 (Planalto), creating CMED: https://www.planalto.gov.br/ccivil_03/leis/2003/l10.742.htm
- Lei 12.401/2011 (Planalto): https://www.planalto.gov.br/ccivil_03/_ato2011-2014/2011/lei/l12401.htm
- Decreto 7.646/2011 (Planalto): https://www.planalto.gov.br/ccivil_03/_ato2011-2014/2011/decreto/d7646.htm
- Lei 14.307/2022 (Planalto): https://www.planalto.gov.br/ccivil_03/_ato2019-2022/2022/lei/l14307.htm
- Lei 14.454/2022 (Planalto): https://www.planalto.gov.br/ccivil_03/_ato2019-2022/2022/lei/l14454.htm
- BioNixus, About page and São Paulo office news: https://www.bionixus.com/about and https://www.bionixus.com/news/bionixus-brazil-office-latam-expansion-2026





